In vitro and in vivo studies on the disposition of mirtazapine in humans

Clinical Drug Investigation

Volumn 13, Issue 1, 1997, Pages 37-46

  Dahl, M L ^a   Voortman, G ^b   Alm, C ^a   Elwin, C E ^a   Delbressine, L ^b   Vos, R ^b   Bogaards, J J P ^c   Bertilsson, L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NV ORGANON   (Netherlands)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUFURALOL; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DRUG METABOLIZING ENZYME; ETHOXYRESORUFIN; MIRTAZAPINE; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; PRIORITY JOURNAL; RACEMIC MIXTURE;

EID: 0031029475     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199713010-00005     Document Type: Article

References (17)

1. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996; 5: 389-402
2. De Boer Th, Ruight GSF, Berendsen HHG. The α-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic neurotransmission. Hum Psychopharmacol 1995; 10 Suppl. 2: S107-S118
3. Sandker GW, Vos RME, Delbressine LPC, et al. Metabolism of three pharmacologically active drugs in isolated human and rat hepatocytes: analysis of interspecies variability and comparison with metabolism in vivo. Xenobiotica 1994; 24: 143-55
4. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-97
5. Bertilsson L, Dahl ML. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 3: 200-23
6. 14C. J Lab Comp Radiopharm 1989; 27: 1055-68
7. Bogaards JJP, van Ommen B, van Bladeren PJ. Human cytochrome P450 enzyme selectivities in the oxidation of chlorinated benzenes. Toxicol Appl Pharmacol 1995; 132: 44-52
8. Leemann T, Transon C, Dayer P. Cylochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1992; 52: 29-34
9. Perella FW. EZ-FIT: a practical curve-fitting microcomputer program for the analysis of enzyme kinetic data on IBM-PC compatible computers. Anal Biochem 1988; 174: 437-47
10. Sanz EJ, Villén T, Alm C, et al. S-mephenytoin hydroxylation phenotype in a Swedish population determined after co-administration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495-9
11. Mahgoub A, Idle JR, Dring DG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 11: 584-6
12. Lennard MS, Silas JH, Smith AJ, et al. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame ionization and nitrogen-selective detection. J Chromatogr 1977; 133: 161-6
13. Evans DAP, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17: 102-5
14. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady slate of mirtazapine from Remeron ® tablets. Hum Psychopharmacol 1995; 10: S97-S 106
15. von Bahr C, Spina E, Birgersson C. et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 1985; 34: 2501-5
16. Inaba T, Jurima M, Mahon WA, et al. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Drug Metab Dispos 1985; 13: 443-8
17. Dahl M-L, Tybring G, Elwin CE, et al. Stereoselective disposition of mianserin is related to debrisoquine hydroxylation polymorphism. Clin Pharmacol Ther 1994; 56: 176-83